Clinical, Diagnostic, and Therapeutic Aspects of Familial Hypercholesterolemia

 

 Buy Article Permissions and Reprints

Heterozygous familial hypercholesterolemia (FH) is a common inherited disorder of lipoprotein metabolism. FH is characterized by elevated levels of low-density lipoprotein cholesterol, the presence of tendon xanthomas, and premature cardiovascular disease. The underlying molecular defect of FH consists of mutations in the gene coding for the low-density-lipoprotein-receptor protein, detection of which provides the only unequivocal diagnosis. Although the cause of FH is monogenic, there is wide variation in the onset and severity of atherosclerotic disease in these patients. Additional atherogenic risk factors of environmental, metabolic, and genetic origin are presumed to influence the clinical phenotype in FH. Criteria used to identify individuals with FH include a combination of clinical characteristics, personal and family history of early coronary artery disease, and biochemical parameters. Since the introduction in 1989 of statins, which have been shown to be effective and to delay or prevent the onset of cardiovascular disease, drug treatment of FH has greatly improved. New lipid-lowering agents are presently being developed for clinical use. This review provides an update on the clinical, diagnostic, and therapeutic aspects of heterozygous familial hypercholesterolemia.

REFERENCES

• 1 Goldstein J L, Hobbs H H, Brown M S. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D The metabolic basis of inherited disease. New York; McGraw-Hill 2001: 2863-2913
  Google Scholar
• 2 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  19;344 1383-1389
  PubMedGoogle Scholar
• 3 Brown M S, Goldstein J L. Receptor-mediated control of cholesterol metabolism.  Science. 1976;  191 150-154
  PubMedGoogle Scholar
• 4 Heath K E, Gahan M, Whittall R A, Humphries S E. Low-density lipoprotein receptor gene (LDLR) World-Wide Website in familial hypercholesterolaemia: update, new features and mutation analysis.  Atherosclerosis. 2001;  154 243-246
  CrossrefPubMedGoogle Scholar
• 5 Villeger L, Abifadel M, Allard D et al.. The UMD-LDLR database: additions to the software and 490 new entries to the database.  Hum Mutat. 2002;  20 81-87
  CrossrefPubMedGoogle Scholar
• 6 LDL-receptor mutation catalogue .Available at: http://www.ucl.ac.uk/fh
• 7 Garcia C K, Wilund K, Arca M et al.. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein.  Science. 2001;  292 1394-1398
  CrossrefPubMedGoogle Scholar
• 8 Tybjaerg-Hansen A. Familial defective apolipoprotein B100. In: Betteridge DJ, Illingworth DR, Sheperd J Lipoproteins in Health and Disease. New York; Oxford University Press 1999: 709-719
  Google Scholar
• 9 Haddad L, Day I N, Hunt S et al.. Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred.  J Lipid Res. 1999;  40 1113-1122
  PubMedGoogle Scholar
• 10 Varret M, Rabes J P, Saint-Jore B et al.. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.  Am J Hum Genet. 1999;  64 1378-1387
  CrossrefPubMedGoogle Scholar
• 11 Hunt S C, Hopkins P N, Bulka K et al.. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred.  Arterioscler Thromb Vasc Biol. 2000;  20 1089-1093
  PubMedGoogle Scholar
• 12 Jansen A C, van Wissen S, Defesche J C, Kastelein J J. Phenotypic variability in familial hypercholesterolaemia: an update.  Curr Opin Lipidol. 2002;  13 165-171
  CrossrefPubMedGoogle Scholar
• 13 Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.  Atherosclerosis. 1999;  142 105-112
  CrossrefPubMedGoogle Scholar
• 14 Sijbrands E J, Westendorp R G, Paola L M et al.. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.  Atherosclerosis. 2000;  149 421-425
  CrossrefPubMedGoogle Scholar
• 15 Hill J S, Hayden M R, Frohlich J, Pritchard P H. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.  Arterioscler Thromb. 1991;  11 290-297
  CrossrefPubMedGoogle Scholar
• 16 Hopkins P N, Stephenson S, Wu L L et al.. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.  Am J Cardiol. 2001;  87 547-553
  CrossrefPubMedGoogle Scholar
• 17 Beaumont V, Jacotot B, Beaumont J L. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases.  Atherosclerosis. 1976;  24 441-450
  CrossrefPubMedGoogle Scholar
• 18 Vuorio A F, Turtola H, Piilahti K M et al.. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study.  Arterioscler Thromb Vasc Biol. 1997;  17 3127-3138
  PubMedGoogle Scholar
• 19 Sauvage Nolting P R, Defesche J C, Buirma R J, Hutten B A, Lansberg P J, Kastelein J J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolemia.  J Intern Med. 2003;  253 161-168
  CrossrefPubMedGoogle Scholar
• 20 Yanagi K, Yamashita S, Kihara S et al.. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance.  Atherosclerosis. 1997;  132 43-51
  CrossrefPubMedGoogle Scholar
• 21 Bertolini S, Cantafora A, Averna M et al.. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.  Arterioscler Thromb Vasc Biol. 2000;  20 E41-E52
  PubMedGoogle Scholar
• 22 Ose L. An update on familial hypercholesterolaemia.  Ann Med. 1999;  31(Suppl 1) 13-18
  PubMedGoogle Scholar
• 23 Heiberg A, Slack J. Family similarities in the age at coronary death in familial hypercholesterolaemia.  Br Med J. 1977;  20;2 493-495
  PubMedGoogle Scholar
• 24 Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.  Circulation. 1995;  92 290-295
  PubMedGoogle Scholar
• 25 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.  Circulation. 2000;  102 1082-1085
  CrossrefPubMedGoogle Scholar
• 26 Wiklund O, Angelin B, Olofsson S O et al.. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.  Lancet. 1990;  335 1360-1363
  CrossrefPubMedGoogle Scholar
• 27 Seed M, Hoppichler F, Reaveley D et al.. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.  N Engl J Med. 1990;  322 1494-1499
  CrossrefPubMedGoogle Scholar
• 28 Carmena R, Lussier-Cacan S, Roy M et al.. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.  Arterioscler Thromb Vasc Biol. 1996;  16 129-136
  PubMedGoogle Scholar
• 29 Davidson M H. Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.  Am J Cardiol. 2001;  87 1A-7A
  PubMedGoogle Scholar
• 30 Howard G, Wagenknecht L E, Burke G L et al.. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study.  JAMA. 1998;  279 119-124
  CrossrefPubMedGoogle Scholar
• 31 Wittekoek M E, De Groot E, Prins M H et al.. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease.  Atherosclerosis. 1999;  146 271-279
  CrossrefPubMedGoogle Scholar
• 32 O'Leary D H, Polak J F, Kronmal R A et al.. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.  N Engl J Med. 1999;  340 14-22
  CrossrefPubMedGoogle Scholar
• 33 Smilde T J, van den Berkmortel F W, Boers G H et al.. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia.  Arterioscler Thromb Vasc Biol. 1998;  18 1958-1963
  PubMedGoogle Scholar
• 34 Smilde T J, van Wissen S, Wollersheim H et al.. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.  Lancet. 2001;  357 577-581
  CrossrefPubMedGoogle Scholar
• 35 Stary H C, Chandler A B, Glagov S et al.. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.  Circulation. 1994;  89 2462-2478
  PubMedGoogle Scholar
• 36 Vogel R A. Cholesterol lowering and endothelial function.  Am J Med. 1999;  107 479-487
  CrossrefPubMedGoogle Scholar
• 37 Neunteufl T, Heher S, Katzenschlager R et al.. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain.  Am J Cardiol. 2000;  86 207-210
  CrossrefPubMedGoogle Scholar
• 38 Suwaidi J A, Hamasaki S, Higano S T et al.. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.  Circulation. 2000;  101 948-954
  CrossrefPubMedGoogle Scholar
• 39 Celermajer D S, Sorensen K E, Gooch V M et al.. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet. 1992;  340 1111-1115
  CrossrefPubMedGoogle Scholar
• 40 Sorensen K E, Celermajer D S, Georgakopoulos D et al.. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level.  J Clin Invest. 1994;  93 50-55
  CrossrefPubMedGoogle Scholar
• 41 Mietus-Snyder M, Malloy M J. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy.  J Pediatr. 1998;  133 35-40
  PubMedGoogle Scholar
• 42 Stroes E S, Koomans H A, de Bruin T W, Rabelink T J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.  Lancet. 1995;  346 467-471
  CrossrefPubMedGoogle Scholar
• 43 Marchesi S, Lupattelli G, Siepi D et al.. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.  J Cardiovasc Pharmacol. 2000;  36 617-621
  PubMedGoogle Scholar
• 44 Holm T, Andreassen A K, Ueland T et al.. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients.  Am J Cardiol. 2001;  87 815-818,A9
  CrossrefPubMedGoogle Scholar
• 45 Alonso R, Mata P, De Andres R et al.. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin.  Atherosclerosis. 2001;  157 423-429
  CrossrefPubMedGoogle Scholar
• 46 Penny W F, Ben Yehuda O, Kuroe K et al.. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein.  J Am Coll Cardiol. 2001;  37 766-774
  CrossrefPubMedGoogle Scholar
• 47 Masumoto A, Hirooka Y, Hironaga K et al.. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin).  Am J Cardiol. 2001;  88 1291-1294
  CrossrefPubMedGoogle Scholar
• 48 Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.  Br Med J. 1991;  303 893-896
  PubMedGoogle Scholar
• 49 Sijbrands E J, Westendorp R G, Defesche J C et al.. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.  BMJ. 2001;  322 1019-1023
  CrossrefPubMedGoogle Scholar
• 50 Burke G L, Arnold A M, Bild D E et al.. Factors associated with healthy aging: the cardiovascular health study.  J Am Geriatr Soc. 2001;  49 254-262
  CrossrefPubMedGoogle Scholar
• 51 Slimane M N, Lestavel S, Sun X et al.. FH-Souassi: a founder frameshift mutation in exon 10 of the LDL- receptor gene, associated with a mild phenotype in Tunisian families.  Atherosclerosis. 2001;  154 557-565
  CrossrefPubMedGoogle Scholar
• 52 Watts G F. Postprandial lipaemia in familial hypercholesterolaemia: clinical and metabolic significance.  Atherosclerosis. 2000;  148 426-428
  PubMedGoogle Scholar
• 53 McNamara J R, Shah P K, Nakajima K et al.. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study.  Atherosclerosis. 2001;  154 229-236
  CrossrefPubMedGoogle Scholar
• 54 Sauvage Nolting P RW, Twickler M B, Dallinga-Thie G M et al.. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy.  Circulation. 2002;  106 788-792
  CrossrefPubMedGoogle Scholar
• 55 Mohrschladt M F, Weverling-Rijnsburger A W, de Man F H et al.. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.  Atherosclerosis. 2000;  148 413-419
  PubMedGoogle Scholar
• 56 Van Wissen S, Trip M D, Smilde T J, de Graaf J, Stalenhoef A F, Kastelein J J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.  Atherosclerosis. 2002;  165 361-366
  CrossrefPubMedGoogle Scholar
• 57 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.  JAMA. 1998;  279 1477-1482
  CrossrefPubMedGoogle Scholar
• 58 Otto C, Ritter M M, Richter W O et al.. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.  Metabolism. 2001;  50 166-170
  CrossrefPubMedGoogle Scholar
• 59 Hobbs H H, Russell D W, Brown M S, Goldstein J L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein.  Annu Rev Genet. 1990;  24 133-170
  CrossrefPubMedGoogle Scholar
• 60 Hobbs H H, Brown M S, Goldstein J L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.  Hum Mutat. 1992;  1 445-466
  CrossrefPubMedGoogle Scholar
• 61 Chaves F J, Real J T, Garcia-Garcia A B et al.. Large rearrangements of the LDL receptor gene and lipid profile in a FH Spanish population.  Eur J Clin Invest. 2001;  31 309-317
  CrossrefPubMedGoogle Scholar
• 62 Tonstad S, Joakimsen O, Stensland-Bugge E et al.. Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects.  Eur J Clin Invest. 1998;  28 971-979
  CrossrefPubMedGoogle Scholar
• 63 Umans-Eckenhausen M AW, Sijbrands E JG, Kastelein J JP, Defesche J C. Low-Density Lipoprotein-receptor gene mutations and cardiovascular risk in a large genetic cascade screening population.  Circulation. 2002;  106 3031-3036
  CrossrefPubMedGoogle Scholar
• 64 Thompson G R, Seed M, Niththyananthan S et al.. Genotypic and phenotypic variation in familial hypercholesterolemia.  Arteriosclerosis. 1989;  9 I75-I80
  PubMedGoogle Scholar
• 65 Kastelein J J, Jukema J W, Zwinderman A H et al.. Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group.  Circulation. 2000;  102 1629-1633
  PubMedGoogle Scholar
• 66 Kastelein J J, Ordovas J M, Wittekoek M E et al.. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women.  Clin Genet. 1999;  56 297-305
  CrossrefPubMedGoogle Scholar
• 67 Wittekoek M E, Pimstone S N, Reymer P W et al.. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia.  Circulation. 1998;  97 729-735
  PubMedGoogle Scholar
• 68 Wittekoek M E, Moll E, Pimstone S N et al.. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia.  Arterioscler Thromb Vasc Biol. 1999;  19 2708-2713
  PubMedGoogle Scholar
• 69 Carmena R, Roy M, Roederer G et al.. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.  Atherosclerosis. 2000;  148 113-124
  CrossrefPubMedGoogle Scholar
• 70 Berglund L, Wiklund O, Eggertsen G et al.. Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy.  J Intern Med. 1993;  233 173-178
  PubMedGoogle Scholar
• 71 Wiegman A, Sijbrands E J, Rodenburg J et al.. The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia.  Pediatr Res. 2003;  53 1008-1012
  CrossrefPubMedGoogle Scholar
• 72 Ordovas J M, Cupples L A, Corella D et al.. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.  Arterioscler Thromb Vasc Biol. 2000;  20 1323-1329
  PubMedGoogle Scholar
• 73 Carmena-Ramon R, Ascaso J F, Real J T et al.. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholesterolemia.  Metabolism. 2001;  50 651-656
  CrossrefPubMedGoogle Scholar
• 74 Leus F R, Wittekoek M E, Prins J et al.. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia.  Atherosclerosis. 2000;  149 371-377
  CrossrefPubMedGoogle Scholar
• 75 Leus F R, Zwart M, Kastelein J J, Voorbij H A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients.  Atherosclerosis. 2001;  154 641-649
  CrossrefPubMedGoogle Scholar
• 76 Wierzbicki A S, Lambert-Hammill M, Lumb P J, Crook M A. Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia.  Hypertension. 2000;  36 808-812
  PubMedGoogle Scholar
• 77 US MedPed program .Available at: http://www.medped.org/who
• 78 Winder A F, Day L B. Premature corneal arcus in familial hypercholesterolemia is characteristic but not a marker of individual coronary risk.  Atherosclerosis. 1997;  134 48
  PubMedGoogle Scholar
• 79 Williams R R, Hopkins P N, Hunt S C et al.. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah.  Arch Intern Med. 1990;  150 582-588
  CrossrefPubMedGoogle Scholar
• 80 Koivisto P V, Koivisto U M, Miettinen T A, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels.  Arterioscler Thromb. 1992;  12 584-592
  PubMedGoogle Scholar
• 81 Nora J J, Lortscher R M, Spangler R D, Bilheimer D W. Familial hypercholesterolemia with “normal” cholesterol in obligate heterozygotes.  Am J Med Genet. 1985;  22 585-591
  CrossrefPubMedGoogle Scholar
• 82 Williams R R, Hunt S C, Schumacher M C et al.. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.  Am J Cardiol. 1993;  72 171-176
  CrossrefPubMedGoogle Scholar
• 83 Heath K E, Gudnason V, Humphries S E, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.  Atherosclerosis. 1999;  143 41-54
  CrossrefPubMedGoogle Scholar
• 84 Fouchier S W, Defesche J C, Umans-Eckenhausen M W, Kastelein J P. The molecular basis of familial hypercholesterolemia in The Netherlands.  Hum Genet. 2001;  109 602-615
  PubMedGoogle Scholar
• 85 The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society.  Eur Heart J. 1988;  9 571-600
  PubMedGoogle Scholar
• 86 Stein E, Strutt K L, Miller E et al.. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C, and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia [abstract].  Atherosclerosis. 2001;  2(Suppl 2) 90
  PubMedGoogle Scholar
• 87 Stein E, Strutt K L, Miller E et al.. ZD44522 is superior to atorvastatin in the treatment of patients with hterozygous familial hypercholesterolemia [abstract].  J Am Coll Cardiol. 2001;  37 (Suppl A) 292A
  PubMedGoogle Scholar
• 88 Kosoglou T, Meyer I, Musiol B et al.. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.  Atherosclerosis. 2000;  151 135
  PubMedGoogle Scholar
• 89 Obarzanek E, Kimm S Y, Barton B A et al.. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (Dros Inf ServC).  Pediatrics. 2001;  107 256-264
  CrossrefPubMedGoogle Scholar
• 90 American Academy of Pediatrics . National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.  Pediatrics. 1992;  89 525-584
  PubMedGoogle Scholar
• 91 Tonstad S, Knudtzon J, Sivertsen M et al.. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia.  J Pediatr. 1996;  129 42-49
  PubMedGoogle Scholar
• 92 Stein E A. Treatment of familial hypercholesterolemia with drugs in children.  Arteriosclerosis. 1989;  9 I145-I151
  PubMedGoogle Scholar
• 93 Ducobu J, Brasseur D, Chaudron J M et al.. Simvastatin use in children.  Lancet. 1992;  339 1488
  PubMedGoogle Scholar
• 94 Knipscheer H C, Boelen C C, Kastelein J J et al.. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.  Pediatr Res. 1996;  39 867-871
  PubMedGoogle Scholar
• 95 Stein E A, Illingworth D R, Kwiterovich Jr P O et al.. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.  JAMA. 1999;  281 137-144
  CrossrefPubMedGoogle Scholar
• 96 Chaves F J, Real J T, Garcia-Garcia A B et al.. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.  J Clin Endocrinol Metab. 2001;  86 4926-4932
  CrossrefPubMedGoogle Scholar
• 97 Vohl M C, Szots F, Lelievre M et al.. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia.  Atherosclerosis. 2002;  160 361-368
  CrossrefPubMedGoogle Scholar
• 98 Sijbrands E J, Lombardi M P, Westendorp R G et al.. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.  Atherosclerosis. 1998;  136 247-254
  CrossrefPubMedGoogle Scholar

 Dr.
J.J. P Kastelein

Department of Vascular Medicine, Academic Medical Center at the University of Amsterdam

Postbox 22660, 1100 DD

Amsterdam, The Netherlands

Email: e.vandongen@amc.uva.nl